middle.news
How Alterity’s $20M Raise Fuels ATH434’s Push Toward Phase 3 Trials
9:36am on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
How Alterity’s $20M Raise Fuels ATH434’s Push Toward Phase 3 Trials
9:36am on Thursday 26th of February, 2026 AEDT
Key Points
Net loss increased to A$9.62 million for H1 FY2026
Positive Phase 2 results reinforce ATH434’s potential in MSA
Preparations underway for mid-2026 FDA End-of-Phase-2 meeting
Raised approximately A$20 million to fund Phase 3 development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ALTERITY THERAPEUTICS (ASX:ATH)
OPEN ARTICLE